News

UroToday5d
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...
UroToday4d
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...
UroToday5d
Performance Large Language Models in Guiding Bladder Cancer Management - Expert Commentary
Bladder cancer (BLCA) management presents complex clinical challenges requiring deep knowledge of current guidelines and clinical expertise. A recent study by Li et al. evaluated the performance of ...
UroToday5d
Shifting Tides: A Survey Analysis of Urologists' Evolving Attitudes Toward Focal Therapy for Prostate Cancer - Beyond the Abstract
Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...
UroToday5d
Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
Prostate cancer (PCa) remains the most prevalent cancer among men and the second leading cause of cancer-related deaths worldwide. Early diagnosis is crucial as it opens up various treatment options ...
UroToday5d
Analytical Validation of MyProstateScore 2.0.
Background/Objectives: Prostate cancer (PCa) is a leading cause of cancer-related deaths among men, with early detection playing a crucial role in improving outcomes. MyProstateScore 2.0 (MPS2), a ...
UroToday5d
Clinical Outcomes and Genomic Alterations in Gleason Score 10 Prostate Cancer.
Background: Gleason score (GS) 10 prostate cancer (PC) is a highly aggressive localized disease. Despite advances in treating high-risk PC, the clinical outcomes and molecular underpinnings of GS 10 ...
UroToday6d
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru ...
UroToday6d
Do differences in secondary treatment explain mortality impact of prostate cancer screening? - A randomized screening trial.
The European Randomized study of screening for prostate cancer (ERSPC) demonstrated a reduction in prostate cancer (PC) mortality via PSA-based screening. We evaluated whether treatments for ...